


U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 2

This listing of claims will replace all prior versions and listing of claims in the application:

Amendments to Claims

1. (Original) A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

A is C or N;

X is phenyl, pyridyl, pyrazinyl, thiaphenyl, quinolinyl, benzofuranyl, oxadiazolyl, diazolylpyridinyl, imidazolylpyridinyl, oxadiazolylphenyl, or benzodioxolyl;

R1 is hydrogen, halogen; or -C1-6alkyl, -cycloC3-6alkyl, or -C1-6alkenyl group, wherein any of the groups is optionally substituted with 1-6 substituents; wherein each substituent is independently halogen, -OH, -CN, or -SO2-C1-6alkyl;

R2, and R3 are each independently hydrogen, halogen, hydroxyl, -CN, -NO2; or -C1-6alkyl, -C2-6alkenyl, -C1-6alkyl(C2-6alkenyl)2, -C0-4alkyl(C3-6cycloalkyl)2, -C0-6alkyl-N(C0-6alkyl)2, -C0-4alkyl-O-C1-6alkyl, -C1-6alkyl-phenyl, -C0-6alkyl-SO2-C1-6alkyl, -C0-6alkyl-C(O)-C0-4alkyl, -C0-6alkyl-C(O)-C0-6alkyl-phenyl, -C0-6alkyl-C(O)-C0-4alkyl-O-C0-6alkyl, -C0-6alkyl-C(O)-C0-6alkyl-O-C0-6alkyl-O-C0-6alkyl-C(O)-C0-6alkyl, -C2-6alkenyl-C(O)-C0-4alkyl-O-C0-6alkyl, -C0-4alkyl-C3-6cycloalkyl-C0-6alkyl-C(O)-C0-6alkyl, -C0-4alkyl-C3-6cycloalkyl-C0-6alkyl-C(O)-C0-6alkyl-N(C0-6alkyl)2, -C0-4alkyl-C3-6cycloalkyl-C0-6alkyl-C(O)-C0-4alkyl-O-C0-6alkyl, -C2-6alkenyl-C(O)-C0-4alkyl-N(C0-6alkyl)-pyridyl, -C0-6alkyl-C(O)-C0-4alkyl-N(C0-4alkyl)2, -C0-6alkyl-C(O)-C0-4alkyl-N(C0-4alkyl)-C3-6cycloalkyl, -C2-6alkenyl-C(O)-C0-4alkyl-N(C0-4alkyl)-C3-6cycloalkyl, -SO2-C0-6alkyl-phenyl, -SO2-C0-6alkyl-(-C0-6alkyl-phenyl)(-C0-6alkyl-phenyl), -C0-4alkyl-SO2-C0-4alkyl-C3-6cycloalkyl-C0-4alkyl-C(O)-C0-4alkyl-O-C0-4alkyl, -S(O)-C0-6alkyl, -P(O)(O-C0-4alkyl)(O-C0-4alkyl), -C2-6alkenyl-C(O)-C0-4alkyl-N(C0-4alkyl)-pyridyl, -S-

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 3

C₁₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)-C(O)-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)-C(O)-N(C₀₋₆alkyl)₂, -C₀₋₄alkyl-S-C₁₋₄alkyl-oxadiazolyl(C₀₋₄alkyl), -C₀₋₄alkyl-C(O)-C₀₋₄alkyl-phenyl, -C₀₋₄alkyl-O-C₀₋₄alkyl-phenyl, -C₀₋₄alkyl-C₃₋₆cycloalkyl-C₀₋₄alkyl-tetrazolyl, -SO₂-N(C₀₋₄alkyl)₂, -C₀₋₄alkyl-S-C₀₋₄alkyl-thiadiazolyl(C₀₋₄alkyl), -C₀₋₄alkyl-S-C₀₋₄alkyl-diazolyl(C₀₋₄alkyl), -C₀₋₄alkyl-S-C₁₋₄alkyl-Si(C₀₋₄alkyl)₃, -C₀₋₄alkyl-S-C₀₋₄alkyl-phenyl(C₀₋₄alkyl), -C₀₋₄alkyl-S-C₀₋₄alkyl-C(O)-C₀₋₄alkyl-O-C₀₋₄alkyl, or -C₀₋₄alkyl-S-C₀₋₄alkyl-C₃₋₆cycloalkyl-C₀₋₄alkyl-C(O)-C₀₋₄alkyl-O-C₀₋₄alkyl, wherein any alkyl, cycloalkyl, alkenyl, phenyl, or pyridyl are each optionally substituted with 1-9 independently halogen, hydroxyl, -C₀₋₄alkyl-O-C₁₋₆alkyl, or -C₀₋₄alkyl-S-C₁₋₆alkyl;

optionally, R₂ forms =O with an adjoining bond;

R₄ is hydrogen, or halogen; and

any ring nitrogen optionally forms *N*-oxide or *N*-chloride.

2. (Original) The compound according to claim 1, wherein A is C.
3. (Original) The compound according to claim 2, wherein X is phenyl.
4. (Original) The compound according to claim 2, wherein X is thiaphenyl.
5. (Original) The compound according to claim 2, wherein X is benzofuranyl.
6. (Original) The compound according to claim 2, wherein X is pyridyl.
7. (Original) The compound according to claim 2, wherein X is pyridyl and
8. (Original) The compound according to claim 2, wherein X is quinolinyl.
9. (Original) The compound according to claim 2, wherein X is oxadiazolyl.
10. (Original) The compound according to claim 2, wherein X is diazolyldipyrindyl or imidazolyldipyrindyl.
11. (Original) The compound according to claim 2, wherein X is pyrazinyl.

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 4


12. (Original) The compound according to claim 2, wherein X is oxadiazolylphenyl.

13. (Original) The compound according to claim 2, wherein X is benzodioxolyl.


14. (Original) The compound according to claim 1, wherein A is N.

15. (Original) The compound according to claim 14, wherein X is phenyl.

16. (Original) The compound according to claim 1, represented by




U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 5



or a pharmaceutically acceptable salt thereof.

17. (Original) The compound according to claim 1, represented by


U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 6




or a pharmaceutically acceptable salt thereof.

18. (Original) The compound according to claim 1, represented by

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 7



U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 8



U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 9

or a pharmaceutically acceptable salt thereof.

19. (Original) The compound according to claim 1, consisting of
6-isopropyl-8-(4'-methanesulfonyl-biphenyl-3-yl)-quinoline;
1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-
ethanone;
1-{3-hydroxy-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-
4-yl}-ethanone;
1-{4-hydroxy-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-
3-yl}-ethanone;
8-(3'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-
quinoline;
8-(4'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-
quinoline;
3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-carbonitrile;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3'-nitro-biphenyl-3-yl)-quinoline;
{4-chloro-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-
yl}-methanol;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acrylic
acid methyl ester;
3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carbaldehyde;
2,2,2-trifluoro-1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-
biphenyl-3-yl}-ethanol;
{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-
methanol;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-acrylic
acid methyl ester;
8-(2'-methanesulfonylmethyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-
ethyl)-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[2'-([1,3,4]thiadiazol-2-
yl)sulfanylmethyl)-biphenyl-3-yl]-quinoline;
{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-
methanol;

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 10

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid methyl ester;

6-(1-methanesulfonyl-1-methyl-ethyl)-8-[2'-(1-methyl-1H-imidazol-2-yl)sulfanylmethyl]-biphenyl-3-yl]-quinoline;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propionic acid methyl;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-prop-2-en-1-ol;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propan-1-ol;

{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-methanol;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propionic acid;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acrylic acid;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-propionic acid;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid;

3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-carbonitrile;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(2'-methylsulfanyl-biphenyl-3-yl)-quinoline;

8-(2'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;

{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acetic acid;

3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carboxylic acid;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-propionic acid methyl ester;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-propionic acid;

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 11

2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-
cyclopropanecarboxylic acid methyl ester;
3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carboxylic
acid amide;
2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-
cyclopropanecarboxylic acid;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-
methyl-propionic acid tert-butyl ester;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-
methyl-propionic acid;
2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-
methyl-propionic acid methyl ester;
{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acetic
acid;
1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-
cyclopropanecarboxylic acid amide;
2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-2-
methyl-propionic acid;
(1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-
ylmethylsulfanylmethyl}-cyclopropyl)-acetic acid;
(1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-
ylmethanesulfonylmethyl}-cyclopropyl)-acetic acid;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic
acid methyl ester;
1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-ylmethyl}-
cyclobutanecarboxylic acid;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{4'-[2-(1H-tetrazol-5-yl)-cyclopropyl]-
biphenyl-3-yl}-quinoline;
(1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-
ylsulfanylmethyl}-cyclopropyl)-acetic acid;
(1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-
sulfonylmethyl}-cyclopropyl)-acetic acid;
3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic
acid;

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 12

or a pharmaceutically acceptable salt thereof.

20. (Original) The compound according to claim 1, consisting of
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(3-methyl-pyridin-2-yl)-phenyl]-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-pyridin-3-yl-phenyl)-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-pyridin-4-yl-phenyl)-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(5-methanesulfonyl-pyridin-3-yl)-phenyl]-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methylsulfanyl-pyridin-2-yl)-phenyl]-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methylsulfanyl-pyridin-3-yl)-phenyl]-quinoline;
2-(6-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methyl-pyridin-3-yl)-phenyl]-quinoline;
5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinic acid ethyl ester;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[6-(propane-2-sulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
8-[3-(6-benzyloxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[5-(2-trimethylsilanyl-ethylsulfanyl)-pyridin-3-yl]-phenyl}-quinoline;
8-{3-[5-(4-fluoro-benzylsulfanyl)-pyridin-3-yl]-phenyl}-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
N-cyclopropyl-5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinamide;

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 13

3-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-5-trifluoromethyl-pyridin-2-ylamine;
dicyclopropyl-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-methanol;
8-[3-(6-ethanesulfonyl-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-propan-2-ol;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[1-oxy-5-(2-trimethylsilyl-ethanesulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
8-(3-{5-[1,2-bis-(4-fluoro-phenyl)-ethanesulfonyl]-1-oxy-pyridin-3-yl}-phenyl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
8-[3-(5-ethanesulfonyl-1-oxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(1-oxy-5-trifluoromethyl-pyridin-3-yl)-phenyl]-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methanesulfonyl-5-methyl-pyridin-3-yl)-phenyl]-quinoline;
3-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-pentan-3-ol;
(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-3-yl)-methanol;
difluoro-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-ylsulfanyl)-acetic acid ethyl ester;
difluoro-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-ylsulfanyl)-acetic acid;
(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-methanol;
1-isopropyl-3-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-urea;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[5-(2-trimethylsilyl-ethanesulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
8-[3-(4-chloro-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 14

(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-(4-methylsulfonyl-phenyl)-methanone;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid isopropylamide;

1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;

6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[6-(4-methoxy-benzyloxy)-pyridin-2-yl]-phenyl}-quinoline;

1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-3-yl)-propan-2-ol;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinic acid;

1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-propan-2-ol;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid methyl ester;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinic acid;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinonitrile;

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinic acid 2,2-dimethyl-propionyloxymethyl ester;

8-[3-(5-chloro-1-oxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;

[1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-ylsulfonylmethyl)-cyclopropyl]-acetic acid;

[1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridine-2-sulfonylmethyl)-cyclopropyl]-acetic acid;

6-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1H-pyridin-2-one

or a pharmaceutically acceptable salt thereof.

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 15

21. (Original) The compound according to claim 1, consisting of
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-thiophen-2-yl-phenyl)-quinoline;
1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-thiophen-
2-yl)-ethanone;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(3-methyl-thiophen-2-yl)-phenyl]-
quinoline;
5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-thiophene-2-
sulfonic acid amide;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-quinolin-3-yl-phenyl)-quinoline;
8-(3-benzo[1,3]dioxol-5-yl-phenyl)-6-(1-methanesulfonyl-1-methyl-ethyl)-
quinoline;
or a pharmaceutically acceptable salt thereof.

22. (Original) The compound according to claim 1, consisting of
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(5-phenyl-pyridin-3-yl)-quinoline;
6-(1-methanesulfonyl-1-methyl-ethyl)-8-(1-oxy-5-phenyl-pyridin-3-yl)-quinoline;
or a pharmaceutically acceptable salt thereof.

23. (Original) A pharmaceutical composition comprising:
a therapeutically effective amount of the compound according to claim 1 or a
pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

24. (Cancelled)

25. (Original) A method of treatment or prevention of asthma; chronic bronchitis;
chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory
distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory
distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial,
fungal or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses;
spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the brain;
psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; osteoarthritis; inflammation; or
cytokine-mediated chronic tissue degeneration comprising the step of administering a
therapeutically effective amount, or a prophylactically effective amount, of the compound
according to claim 1 or a pharmaceutically acceptable salt thereof.

U.S.S.N. 10/517,416
CASE NO. MC050YP
PAGE NO. 16

26. (Original) A method of treatment or prevention of allergic rhinitis, allergic conjunctivitis, eosinophilic granuloma, osteoporosis, arterial restenosis, atherosclerosis, reperfusion injury of the myocardium chronic glomerulonephritis, vernal conjunctivitis, cachexia, transplant rejection, or graft versus host disease, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

27. (Original) A method of treatment or prevention of depression, memory impairment, monopolar depression, Parkinson disease, Alzheimer's disease, acute and chronic multiple sclerosis, psoriasis, benign or malignant proliferative skin diseases, atopic dermatitis, urticaria, cancer, tumour growth or cancerous invasion of normal tissues, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

28. (Original) A method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of compound of claim 1.

29. (Presently Amended) A method of enhancing cognition in a healthy subject comprising administering a safe, non-emetic, cognition enhancing amount of compound of claim 1.

30. (Original) A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 40 years of age or older.

31. (Original) A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 55 years of age or older.